McLean G, Lawrence M, Simpson R, Mercer S W
General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, I Horselethill Road, Glasgow, Scotland, G12 9LX, UK.
Institute for Applied Health Research, School of Health and Life Sciences Glasgow Caledonian University, Glasgow, G4 0BA, UK.
BMC Neurol. 2017 May 15;17(1):92. doi: 10.1186/s12883-017-0876-4.
Mindfulness based stress reduction (MBSR) is increasingly being used to improve outcomes such as stress and depression in a range of long-term conditions (LTCs). While systematic reviews on MBSR have taken place for a number of conditions there remains limited information on its impact on individuals with Parkinson's disease (PD).
Medline, Central, Embase, Amed, CINAHAL were searched in March 2016. These databases were searched using a combination of MeSH subject headings where available and keywords in the title and abstracts. We also searched the reference lists of related reviews. Study quality was assessed based on questions from the Cochrane Collaboration risk of bias tool.
Two interventions and three papers with a total of 66 participants were included. The interventions were undertaken in Belgium (n = 27) and the USA (n = 39). One study reported significantly increased grey matter density (GMD) in the brains of the MBSR group compared to the usual care group. Significant improvements were reported in one study for a number of outcomes including PD outcomes, depression, mindfulness, and quality of life indicators. Only one intervention was of reasonable quality and both interventions failed to control for potential confounders in the analysis. Adverse events and reasons for drop-outs were not reported. There was also no reporting on the costs/benefits of the intervention or how they affected health service utilisation.
This systematic review found limited and inconclusive evidence of the effectiveness of MBSR for PD patients. Both of the included interventions claimed positive effects for PD patients but significant outcomes were often contradicted by other results. Further trials with larger sample sizes, control groups and longer follow-ups are needed before the evidence for MBSR in PD can be conclusively judged.
基于正念减压疗法(MBSR)越来越多地被用于改善一系列慢性病(LTC)患者的应激和抑郁等状况。虽然针对多种疾病对MBSR进行了系统评价,但关于其对帕金森病(PD)患者影响的信息仍然有限。
于2016年3月检索了医学期刊数据库(Medline)、循证医学图书馆(Central)、荷兰医学文摘数据库(Embase)、澳大利亚医学数据库(Amed)、护理学与健康领域数据库(CINAHL)。使用适用的医学主题词(MeSH)和标题及摘要中的关键词组合检索这些数据库。我们还检索了相关综述的参考文献列表。根据Cochrane协作网偏倚风险工具中的问题评估研究质量。
纳入了两项干预措施和三篇论文,共66名参与者。干预措施分别在比利时(n = 27)和美国(n = 39)进行。一项研究报告称,与常规护理组相比,MBSR组患者大脑中的灰质密度(GMD)显著增加。一项研究报告了包括帕金森病相关指标、抑郁、正念和生活质量指标在内的多项结局有显著改善。只有一项干预措施质量尚可,且两项干预措施在分析中均未控制潜在的混杂因素。未报告不良事件和退出原因。也未报告干预措施的成本/效益或其对卫生服务利用的影响。
本系统评价发现,关于MBSR对帕金森病患者有效性的证据有限且尚无定论。纳入的两项干预措施均称对帕金森病患者有积极效果,但显著结果常与其他结果相矛盾。在能够最终判定MBSR对帕金森病有效性的证据之前,需要进行更大样本量、设置对照组且随访时间更长的进一步试验。